Valve-in-valve hemodynamics of 20-mm transcatheter aortic valves in small bioprostheses

Transcatheter aortic valve (TAV) implantation is a treatment for selected patients with failing bioprostheses. We previously showed that currently available SAPIEN (Edwards Lifesciences, Irvine, CA) TAV sizes did not yield acceptable valve-in-valve (VIV) hemodynamics in small degenerated bioprostheses because optimal TAV function requires full stent expansion to its nominal size.

Go to the Article

STAY UPDATED

Sign up for our newsletter today